Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings

Table 2 Concomitant antibiotic use over the period of 12 months prior to initiating ALIS

	ALIS cohort
Antibiotic class/antibiotic	(N = 331)
GBT regimen^a	74 (22.4)
Macrolide	133 (40.2)
Azithromycin	127 (38.4)
Clarithromycin	16 (4.8)
Ethambutol	83 (25.1)
Rifamycin	87 (26.3)
Rifabutin	13 (3.9)
Rifampin	82 (24.8)
Aminoglycoside	47 (14.2)
Amikacin sulfate	39 (11.8)
Tobramycin	14 (4.2)
Fluoroquinolone	96 (29.0)
Ciprofloxacin	50 (15.1)
Levofloxacin	61 (18.4)
Moxifloxacin	9 (2.7)
Other antibiotics classes
Cephalosporin	6 (1.8)
Carbapenem	8 (2.4)
Oxazolidinone	14 (4.2)
Glycylcycline	5 (1.5)
Tetracycline	37 (11.2)

All data are presented as n (%)
ALIS amikacin liposome inhalation suspension, GBT guideline-based treatment
^aGBT based on American Thoracic Society/European Respiratory Society/European Society of Clinical Microbiology and Infectious Diseases/Infectious Diseases Society of America clinical practice guidelines [23] guidelines refer to three-drug combination of a macrolide plus ethambutol with a third antibiotic, typically a rifamycin

ISSN: 1471-2466